Progenics Pharmaceuticals Expands Leadership Team with Appointment of Asha Das, M.D. as Chief Medical Officer
January 02 2019 - 8:30AM
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company
developing innovative medicines and imaging analysis technology for
targeting and treating cancer, today announced the appointment of
Asha Das, M.D. to the newly created role of Chief Medical Officer.
Dr. Das brings 13 years of drug development experience, including
leading activities related to the approval and launch of Avastin®
in multiple indications at Genentech, as well as a decade of
clinical practice and academic expertise in neurology and
neuro-oncology.
“Asha is a talented clinician and a proven
oncology drug development leader,” stated Mark Baker, CEO of
Progenics. “Her experience developing and executing
registrational studies will be invaluable to Progenics as we
advance our portfolio of PSMA-targeted imaging and therapeutic
agents and look to developing new indications for AZEDRA. We are
delighted to welcome her to the Company.”
Dr. Das most recently served as Tocagen’s Chief
Medical Officer, where she led the development of the company’s
cancer-selective gene therapy platform. From April 2008 to April
2015, Dr. Das served at Genentech, a member of the Roche Group, in
positions of increasing responsibility, initially as Associate
Medical Director and ultimately as Group Medical Director. She was
responsible for leading activities related to the approval and
launch of Avastin in recurrent glioblastoma, expansion into
platinum-resistant ovarian cancer and metastatic cervical cancer as
well as clinical activities related to TECENTRIQ®. From 2005 to
2008, Dr. Das served as Associate Medical Director at Eisai Inc., a
pharmaceutical company, where she focused on clinical activities
related to the oncology therapeutics HALAVEN® and LENVIMA™. Prior
to that, Dr. Das was head of the neuro-oncology program at
Cedars-Sinai Medical Center.
“This is an exciting time to be joining
Progenics, with the launch of AZEDRA in adult and pediatric
patients with ultra-rare cancers, and the recent progress in the
Company’s pipeline of radiopharmaceuticals, a new class of drugs,”
commented Dr. Das. “In addition, PyL represents an opportunity to
change how prostate cancer is diagnosed and managed, while 1095
leverages the power of our PSMA-targeted radiopharmaceutical
approach to potentially improve outcomes for patients with prostate
cancer. I look forward to leading these transformative programs and
advancing Progenics’ mission to find, fight and follow
cancer.”
Dr. Das is certified in neurology by the
American Board of Psychiatry and Neurology and in the sub-specialty
of neuro-oncology by the United Council for Neurologic
Subspecialties and previously served as a clinical fellow in
neuro-oncology at Massachusetts General Hospital. Dr. Das completed
her residency in neurology at Cornell Medical Center and has held
academic appointments at the University of California, Los Angeles;
University of California, San Francisco; and National University of
Singapore. Dr. Das obtained her medical degree and bachelor’s
degree from Cornell University.
About Progenics
Progenics develops innovative medicines and
other technologies to target and treat cancer, including:
therapeutic agents designed to treat cancer (AZEDRA® (iobenguane I
131), 1095, and PSMA TTC); prostate-specific membrane antigen
(“PSMA”) targeted imaging agent for prostate cancer (PyL™); and
imaging analysis technology (PSMA AI and aBSI). Progenics has two
commercial products, AZEDRA, for the treatment of patients with
unresectable, locally advanced or metastatic pheochromocytoma or
paraganglioma (rare neuroendocrine tumors of neural crest origin)
who require systemic anticancer therapy and RELISTOR®
(methylnaltrexone bromide) for the treatment of opioid-induced
constipation, which is partnered with Bausch Health Companies
Inc.
This press release contains "forward-looking
statements" regarding future events. Statements contained in this
communication that refer to Progenics' estimated or anticipated
future results or other non-historical facts are forward-looking
statements that reflect Progenics' current perspective of existing
trends and information as of the date of this communication.
Forward looking statements are generally accompanied by words such
as "anticipate," "believe," "plan," "could," "should," "estimate,"
"expect," "forecast," "outlook," "guidance," "intend," "may,"
"might," "will," "possible," "potential," "predict," "project," or
other similar words, phrases or expressions. Such statements are
predictions only, and are subject to risks and uncertainties that
could cause actual events or results to differ materially. These
risks and uncertainties include, among others, market acceptance
for approved products; the cost, timing and unpredictability of
results of clinical trials and other development activities and
collaborations, such as the anticipated launch of a Phase 3 trial
for PyL; our ability to successfully develop and commercialize
products, such as PyL, that incorporate licensed intellectual
property; the effectiveness of the efforts of our partners to
market and sell products on which we collaborate and the royalty
revenue generated thereby; generic and other competition; the
possible impairment of, inability to obtain and costs of obtaining
intellectual property rights; possible product safety or efficacy
concerns, general business, financial, regulatory and accounting
matters, litigation and other risks. More information concerning
Progenics and such risks and uncertainties is available on its
website, and in its press releases and reports it files with the
U.S. Securities and Exchange Commission, including those risk
factors included in its Annual Report on Form 10-K for the fiscal
year ended December 31, 2017, as updated in its subsequent
Quarterly Reports on Form 10-Q. Progenics is providing the
information in this press release as of its date and, except as
expressly required by law, Progenics disclaims any intent or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
circumstances or otherwise.
Additional information concerning Progenics and
its business may be available in press releases or other public
announcements and public filings made after this release. For more
information, please visit www.progenics.com. Information on or
accessed through our website or social media sites is not included
in the company's SEC filings.
(PGNX-F)
Contact: |
Melissa DownsInvestor Relations(646)
975-2533mdowns@progenics.com |
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Sep 2023 to Sep 2024